Bivalent RSV Vaccine (IN006)

BIOLOGICAL2 trials

Sponsors

Shenzhen Shenxin Biotechnology Co., Ltd

Conditions

Respiratory Syncytial Virus Infections

Phase 1

A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adults

Not yet recruitingNCT06287450

Shenzhen Shenxin Biotechnology Co., LtdRespiratory Syncytial Virus Infections

Start: 2026-12-01End: 2028-04-01Target: 200Updated: 2026-04-13

A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adult Aged 18 Years and Above

Active, not recruitingNCT06645665

Shenzhen Shenxin Biotechnology Co., LtdRespiratory Syncytial Virus Infections

Start: 2024-11-11End: 2027-04-01Target: 240Updated: 2026-04-02